In 1144 men with PSMA-positive metastatic hormone-sensitive prostate cancer, adding 177Lu-PSMA-617 to ADT plus ARPI improved radiographic progression-free survival (HR 0·72) at a second interim analysis; grade ≥3 adverse events 51% vs 43%.
RCTn = 1,144
Tagawa et al. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial